Sold by: Next Move Strategy Consulting
Deployed on AWS
The global Leukemia Therapeutics Market is expected to reach $29 billion by 2030, exhibiting a CAGR of 9% from 2024 to 2030. The substantial growth is attributed to the emergence of innovative treatments like bone marrow transplants and menine inhibition in cancer therapeutics. These advancements not only enhance patient outcomes but also hold the potential to positively impact the healthcare sector, driving further market expansion.
Overview
The global Leukemia Therapeutics Market size was valued at $17.34 billion in 2023, and is predicted to reach $29 billion by 2030, with a CAGR of 9% from 2024 to 2030. Leukemia, also known as blood cancer impacts the blood and bone marrow. It primarily involves the uncontrolled growth of abnormal white blood cells that are in charge for fighting contaminations in the body.
The leukemia therapeutics market is significantly growing due to the development of breakthrough treatments such as bone marrow transplants and menine inhibition applied in the field of cancer therapeutics. Such treatments offer positive and improved patient outcomes and the potential to benefit the healthcare industry, further contributing to the market growth.
Request for a FREE sample of the report, here, https://www.nextmsc.com/leukemia-therapeutics-market/request-sample
Moreover, the growth in the elderly population worldwide, who are more prone to chronic conditions, including leukemia, is leading to a surge in government funding for clinical trials and advancements in cancer therapies. This, in turn, boosts the growth of the market.
However, the high cost of treatment and lengthy and rigorous regulatory approval process for leukemia drug developments significantly restrain the leukemia therapeutics market. On the contrary, the introduction of targeted therapies such as Chimeric Antigen Receptor (CAR)-T cell therapy for treating a broader spectrum of blood cancers is anticipated to create ample opportunities for the growth of the leukemia therapeutics market in the coming years.
The leukemia therapeutics market share is divided on the basis of treatment type, type of leukemia, mode of administration, gender, and region. On the basis of type of leukemia, the market is divided into acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and others. Based on treatment type, the market is categorized into chemotherapy and targeted therapy.
On the basis of route of administration, the market is classified into oral mode and injectable mode. On the basis of distribution channel, the market is bifurcated into hospital pharmacy and retail pharmacy. The regional breakdown and analysis of each of the aforesaid segments includes regions, such as North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
Access the full report, here, https://www.nextmsc.com/report/leukemia-therapeutics-market
North America holds the dominant share of the leukemia therapeutics market. The market is analyzed across the U.S., Canada, and Mexico. The growing research in regenerative medicines to treat blood cancer such as lymphoma and leukemia along with the growing awareness of cell-based therapies are boosting the growth of the market in this region. On the other hand, the Asia-Pacific region is emerging as the fastest-growing sector in the leukemia therapeutics market, primarily driven by intensified research efforts on existing medications.
Various market players operating in the leukemia therapeutics industry include AbbVie, Inc., BristolMyers Squibb, F. Hoffmann-La Roche AG, Pfizer, Inc., Novartis AG, Sanofi S.A., Amgen, Inc., SymBio Pharmaceuticals Limited, Genmab A/S, Gilead Sciences, Inc. and others. These market players opt for various strategies, such as research and development and product launches, to maintain their dominance in the leukemia therapeutics market.
Details
Delivery method
Deployed on AWS
New
Introducing multi-product solutions
You can now purchase comprehensive solutions tailored to use cases and industries.
Features and programs
Financing for AWS Marketplace purchases
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
Pricing
This product is available free of charge. Free subscriptions have no end date and may be canceled any time.
Additional AWS infrastructure costs may apply. Use the AWS Pricing Calculator to estimate your infrastructure costs.
Dimensions summary
This listing offers a single pricing dimension: Product Access (Units). It is free, so you pay nothing to subscribe and gain access to the product. There are no tiers, usage add-ons, or size-based options to compare. You get access under one flat, no-cost dimension. Reports are delivered digitally by email after purchase confirmation, typically within 24 to 48 hours.
Top-of-mind questions for buyers
It grants subscriber access to the product at no cost. You do not pay for the unit itself. The associated market research report is then delivered to you digitally, so access covers receiving and downloading the report content.
Reports are delivered by email to your registered address after purchase confirmation, usually within 24 to 48 hours. You receive digital formats such as PDF, Excel, or Word, or a download link. Printed copies, if requested, ship within three working days of payment.
No. All sales are final. The vendor does not accept cancellations, returns, or refunds once a report has been sold and delivered. Reports are digital and contain sensitive research data. Review all terms before purchasing, and contact customer service with questions beforehand.
www.nextmsc.com+1
Helpful?
Vendor refund policy
Not applicable - product available free of charge.
Legal
Vendor terms and conditions
Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA) .
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Additional details
You will receive access to the following data sets.
Data set name | Type | Historical revisions | Future revisions | Sensitive information | Data dictionaries | Data samples |
|---|---|---|---|---|---|---|
NMSC_MarketResearch | All historical revisions | All future revisions | Not included | Not included |
Resources
Vendor resources
Similar products
60-minute live analyst briefing focused on the Leukemia Therapeutics Market, helping healthcare and life sciences leaders optimize AWS-cloud strategies for oncology analytics, AI-driven forecasting, clinical data scaling, and precision medicine planning.
Expert consultation and strategic market assessment regarding the global Agentic AI landscape (2024–2030). Includes a dedicated analyst briefing to align market trends with your business objectives.
60-minute live analyst briefing focused on the Base Editing Market (2026–2035), helping biotech, pharma, and genomic service leaders optimize AWS-based genomics infrastructure, AI-driven R&D scaling, and strategic investment planning.
Unlock strategic insights into the Two-Wheelers Market with our expert consulting engagement. Includes a live analyst briefing and comprehensive market intelligence to drive your mobility, EV, and investment strategies on Amazon Web Services (AWS).